02:10 , Jan 8, 2013 |  BC Extra  |  Financial News

Burrill adds bankers Frank, Tanner

Burrill & Co. hired Frederick Frank as vice chairman of the firm and chairman of the firm's Burrill Securities broker dealer arm, and Mary Tanner as senior managing director of both companies, effective Jan. 15....
08:00 , Feb 22, 2010 |  BioCentury  |  Finance

Ebb & flow

Marina Bozilenko joined William Blair & Co. as head of biotechnology and pharma in the healthcare investment banking group. She was a principal at private equity firm Kidd & Co. and prior to that a...
07:00 , Jun 29, 2009 |  BioCentury  |  Finance

Ebb & Flow

Novo's crossover ambitions Novo A/S has tripled its commitment to life sciences venture investment from roughly $100 million to $300 million annually. Last week, Novo unveiled its evergreen Novo Growth Equity fund, which will invest...
07:00 , Oct 6, 2008 |  BioCentury  |  Finance

Underwriting biotech

Underwriting biotech Underwriting biotech It's not yet clear what effect the collapse of major financial institutions such as Bear Stearns and Lehman Brothers, along with the sale of Merrill Lynch, may have on biotech's financing...
07:00 , Aug 11, 2008 |  BC Week In Review  |  Company News

Telik management update

Telik Inc. (NASDAQ:TELK), Palo Alto, Calif.   Business: Cancer   Hired: Stefan Ryser as SVP of corporate strategy, formerly managing partner at Bear Stearns Health Innoventures L.P.  ...
00:28 , Jul 16, 2008 |  BC Extra  |  Top Story

ViroPharma to acquire Lev

ViroPharma (NASDAQ:VPHM) will acquire Lev (OTCBB:LEVP) for $2.75 per share, or $442.9 million in stock and cash. The price is a 49% premium to Lev's close of $1.85 on Monday, before the deal was announced....
07:00 , Jun 30, 2008 |  BioCentury  |  Finance

Ebb & Flow

Why is this quarter different from all other quarters? It seems likely that not a single venture-backed company will debut on a U.S. exchange. That hasn’t happened since 1978, according to the National Venture Association...
07:00 , Jun 9, 2008 |  BioCentury  |  Finance

Ebb & Flow

Having gotten his hands on 215 pages of documents from Biogen Idec (NASDAQ:BIIB) under judicial order by the Delaware Chancery Court, activist investor Carl Icahn last week leveled new charges that at least one potential...
07:00 , Jun 2, 2008 |  BioCentury  |  Finance

Ebb & Flow

Southern exposure By Stacy Lawrence & Mike Ward With only one Phase I compound left in its pipeline, cancer company Sonus (NASDAQ:SNUS) last week announced a 50-50 reverse merger with private Canadian cancer company OncoGenex...
07:00 , Apr 28, 2008 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/18 cls Alizyme (LSE:AZM) Piper Jaffray Sam Fazeli Price target Buy -23% 29.5p Fazeli lowered his target to 94.5p from 111p after the company...